Polaris Partners on Wednesday said it’s promoted Kevin Bitterman, a principal focused on health care investing, to partner of the firm.
Bitterman has been with Waltham-based Polaris since 2004. He cofounded Sirtris Pharmaceuticals, which was acquired by Glaxo Smith Kline in 2008, and Genocea Biosciences (Nasdaq: GNCA), which went public in February. He was also involved with the formation last year of Editas Medicine, where he is serving as interim chief executive.
Bitterman holds a PhD in genetics at Harvard Medical School.
“His passion for science, entrepreneurial spirit, and pragmatic approach to company building has proven to be a tremendous asset for our portfolio,” said Amir Nashat, Polaris managing partner, in a news release.
Polaris plans to open a new office in the Boston Seaport on May 1, on Fan Pier’s One Marina Park Drive, said managing partner Dave Barrett. The firm’s Waltham office will remain open through 2016.
Kyle Alspach has worked in journalism in Massachusetts since 2005 and was one of the original staff writers at BetaBoston.
Follow Kyle on Twitter